A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor α chains

被引:44
|
作者
England, BP
Balasubramanian, P
Uings, I
Bethell, S
Chen, MJ
Schatz, PJ
Yin, Q
Chen, YF
Whitehorn, EA
Tsavaler, A
Martens, CL
Barrett, RW
McKinnon, M
机构
[1] Affymax Res Inst, Palo Alto, CA 94304 USA
[2] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Cell Biol Unit, Stevenage SG1 2NY, Herts, England
[3] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Prot Sci Unit, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1073/pnas.110053997
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Two series of peptides that specifically bind to the extracellular domain of the alpha chain of the human interleukin-5 receptor (IL-5R alpha). but share no primary sequence homology to IL-5, were identified from libraries of random recombinant peptides. Affinity maturation procedures generated a 19-aa peptide that binds to the IL-5 receptor alpha/beta heterodimer complex with an affinity equal to that of IL-5 and is a potent and specific antagonist of IL-5 activity in a human eosinophil adhesion assay. The active form of the peptide is a disulfide-crosslinked dimer that forms spontaneously in solution. Gel filtration analysis, receptor-binding studies, and analytical ultracentrifugation reveal that the dimeric peptide binds simultaneously to two receptor alpha chains in solution. Furthermore, the dimer peptide, but not IL-5, can activate a chimeric receptor consisting of the IL-5R alpha extracellular domain fused to the intracellular domain of the epidermal growth factor receptor, thus demonstrating that the peptide also promotes receptor dimerization in a cellular context. The functional antagonism produced by the bivalent interaction of the dimeric peptide with two IL-5R alpha chains represents a distinctive mechanism for the antagonism of cytokines that use heteromeric receptors.
引用
收藏
页码:6862 / 6867
页数:6
相关论文
共 50 条
  • [21] Interleukin-5 and allergic inflammation
    O'Byrne, PM
    Wood, L
    CLINICAL AND EXPERIMENTAL ALLERGY, 1999, 29 (05): : 573 - 575
  • [22] Illuminating interleukin-5 data
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (10) : 715 - 715
  • [23] Interleukin-5 and IL-5 receptor in health and diseases
    Takatsu, Kiyoshi
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2011, 87 (08): : 463 - 485
  • [24] Interleukin-5 - Immunological functions and therapeutic potential of a putative antagonist
    Takatsu, K
    BIODRUGS, 1997, 8 (01) : 33 - 45
  • [25] INCREASED EXPRESSION OF INTERLEUKIN-5 RECEPTOR GENE IN ASTHMA
    PLOYSONGSANG, Y
    HUMBERT, M
    YING, S
    YASRUEL, Z
    DURHAM, S
    KAY, AB
    HAMID, Q
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) : 279 - 279
  • [26] Dissociation of production of interleukin-4 and interleukin-5
    Sewell, WA
    Mu, HH
    IMMUNOLOGY AND CELL BIOLOGY, 1996, 74 (03): : 274 - 277
  • [27] STRUCTURE AND FUNCTION OF INTERLEUKIN-4 AND INTERLEUKIN-5
    SIDERAS, P
    NOMA, T
    HONJO, T
    IMMUNOLOGICAL REVIEWS, 1988, 102 : 189 - 210
  • [28] INTERLEUKIN-4 AND INTERLEUKIN-5 - MECHANISMS OF ACTION
    SEVERINSON, E
    MOON, HB
    BERGSTEDTLINDQVIST, S
    PERSSON, U
    HEUSSER, C
    STAVNEZER, J
    MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION II, 1989, 254 : 125 - 133
  • [29] Mitogenic effects of interleukin-5 on microglia
    Ringheim, GE
    NEUROSCIENCE LETTERS, 1995, 201 (02) : 131 - 134
  • [30] Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
    Bagnasco, Diego
    Ferrando, Matteo
    Caminati, Marco
    Bragantini, Alice
    Puggioni, Francesca
    Varricchi, Gilda
    Passalacqua, Giovanni
    Canonica, Giorgio Walter
    DRUG SAFETY, 2017, 40 (07) : 559 - 570